
Genotype and left ventricular (LV) scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non‐ischemic dilated cardiomyopathy (DCM). Therefore, the study investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM. Classification of patients with DCM according to genotype and LGE improves MVA and ESHF prediction. Therefore, scar assessment with CMR and genotyping should be considered to select patients for primary prevention ICD placement.
Like
Save
Share